The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.50
Bid: 28.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.571%)
Open: 28.50
High: 29.00
Low: 28.50
Prev. Close: 28.50
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

International Business Development Appointments

8 Oct 2010 10:30

RNS Number : 0953U
Ilika plc
08 October 2010
 



8 October 2010

Ilika plc

("Ilika" or the "Company" or the "Group")

Ilika expands its business development activities in the US and Asia

 

United States

Ilika is pleased to announce the appointment of the JGW Group ("JGW") to help develop new business opportunities primarily in the US aerospace and defence sectors. JGW, which is headquartered in Virginia, is well placed to access US Department of defence sites and has a proven track record of helping clients secure government contracts.

Alongside JGW, the Company announces the appointment of Stuardo Robles as a new business development director. Stuardo is a senior engineer and marketing professional with more than fifteen years of comprehensive business and technical leadership in manufacturing systems and related services in the global semiconductor industry, primarily with Applied Materials Inc.

Japan

Ilika has extended its relationship with Blue Rise Partners ("Blue Rise"). In addition to representing Ilika in the electronics and energy sectors, Blue Rise has appointed Takashi Matsui who will seek out opportunities for the company in the bio-medical sector.

Takeshi Ishikawa, business development director for Asia who has been with the company since 2005 and instrumental in the securing of a number of significant contracts, is relocating to Tokyo to spend more time addressing the increased interest that the Company is enjoying from Japanese multinationals.

Graeme Purdy, Ilika's CEO, commented, "These appointments significantly strengthen Ilika's ability to support its existing customer base and market its services to a much wider audience."

For more information contact:

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

+44 (0) 23 80111400

 

Nomura Code Securities Limited

Phil Walker / Christopher Golden

+44 (0) 20 7776 1200

Pelham Bell Pottinger

Archie Berens / Olly Scott / Francesca Tuckett

 

+44 (0) 20 7861 3232

 

About Ilika

Ilika (AIM: IKA) is an advanced materials company which accelerates the discovery of new and patentable materials using its unique high throughput technologies (''HTT'') process for identified end uses in the energy, electronics and biomedical sectors. This process enables hundreds of scalable materials to be made in a single, automated operation and subsequently tested for key properties.

Traditionally, materials development has been a slow and arduous task, with manual, sequential methods used to make samples of material that are then tested for suitability. On average, it takes between seven and 10 years to move from an initial discovery through to the first commercial prototype. Experiments carried out by the Company can be executed 10 to 100 times faster than using traditional techniques.

The Company focuses on three principal sectors and has a number of active development programmes addressing markets within each sector:

Energy - developing innovative new materials for Lithium-ion batteries for vehicles for Toyota; developing high capacity hydrogen storage materials with Shell Hydrogen and Johnson Matthey through joint development programmes; developing cheaper alternatives to Platinum electrodes for use in fuel cells through a grant-funded project with the Carbon Trust; developing new materials for use in fuel cells for the transport sector for a major vehicle manufacturer; and carrying out in-house research on film photovoltaic solar cells.

Electronics - developing lead-free piezoelectric materials through a joint development programme with CeramTec; and developing phase change memory materials for high capacity memory.

Biomedical - developing polymers to enable the filtering of somatic stem cells from blood with a major global supplier of filters; it has been selling its CryoSkin® and MySkin® products for the treatment of burns and wounds in the UK through a specialist distributor and intends to commence clinical trials of its corneal bandage candidate.

The Group's commercialisation strategy is to enter into joint development or licensing agreements with large multinational companies which are seeking to commercialise products developed using the intellectual property created through jointly-funded programmes. Current commercialisation partners include large multinational companies such as Toyota, Shell, Johnson Matthey and CeramTec. The Company generates revenues from three sources: licensing and milestone payments from joint development programmes; fee for service from contract research projects; and from sales of CryoSkin® and MySkin®.

www.ilika.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGCBDGUDGBGGI
Date   Source Headline
13th May 202410:16 amRNSPosting of Circular & Notice of General Meeting
10th May 20243:02 pmRNSResult of Placing
10th May 20247:00 amRNSProposed Placing and Open Offer & Notice of GM
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.